加盟WTO對中國製藥產業的影響與商機：第2版 是由出版商Pharmalicensing Ltd.在2006年03月所出版的。
這份英文市場調查報告書包含28 pages 價格從美金795起跳。
Abstract
Key points covered in this report:
- The development of the Chinese pharmaceutical industry and its current
status
- Changes in the industry on China's accession to the WTO
- The competitiveness of the Chinese pharmaceutical industry in the
international market
- The R&D and business opportunities for pharmaceutical firms considering
alliances in China
- Significant points for consideration for companies looking to capture
business opportunities in China.
This report discusses the state of the Chinese pharmaceutical industry and the
opportunities available to companies doing business in China, and is aimed at
individuals in business development and technology transfer looking to expand
into China. China is one of the largest pharmaceuticals-producing countries in
the world, and as it joins the World Trade Organization (WTO), it will need to
integrate more completely into the global economy. This international
competition will place an intense pressure on the Chinese pharmaceutical
industry, and further open the door to a lucrative market for non-Chinese
companies, especially for pharmaceutical producers and manufacturers.
This second edition, updated with new figures and tables based on Chinese
official statistics, provides an overview of the development of the Chinese
pharmaceutical industry and its current status, and a discussion of the
competitiveness of the Chinese pharmaceutical industry in the international
market. The report also provides an analysis of the business opportunities for
pharmaceutical firms considering alliances in China, based on this research
and the commitments made by Chinese authorities at the time of accession to
the WTO, and concludes by highlighting the significant points for
consideration for companies looking to capture such business opportunities in
China.
The appendices include two case studies that explore examples of a
'Sino-foreign equity joint venture' and a 'Wholly foreign-owned company' in
China, references, a glossary of terms, the source data used in the figures,
and a resources section.
This report is suitable to individuals responsible for and interested in:
- Board and executive management
- Business development
- Licensing/partnering
- Deal making
- Business strategy
Case studies:
- Sino-Swed Pharmaceutical Corp. LTD (SSPC)
- Pfizer (China) Pharmaceuticals Limited
China has established a pharmaceutical industry structure, and has become one
of the largest pharmaceuticals-producing countries in the world. As China
joins the World Trade Organization (WTO), it will need to integrate more
completely into the global economy. This international competition will place
an intense pressure on the Chinese pharmaceutical industry, and further open
the door to a lucrative market for non-Chinese companies, especially for
pharmaceutical producers and manufacturers. Accession to the WTO will bind
China by fundamental WTO principles, such as improved transparency and the
strengthening of commercial legal procedures. China's WTO commitments include
the tightening of rules on intellectual property, tariff concessions, and
market access of non-Chinese service suppliers engaging in the distribution of
pharmaceuticals. All such moves will create additional business opportunities
for non-Chinese pharmaceutical companies in China, and in turn, place an
intense pressure on the Chinese pharmaceutical industry.
This report will discuss the state of the Chinese pharmaceutical industry and
the opportunities available to companies doing business in China, based on
Chinese official statistics. Section 2 provides an overview of the development
of the Chinese pharmaceutical industry, and its current status. Section 3
discusses the competitiveness of the Chinese pharmaceutical industry in the
international market. Section 4 provides an analysis of the business
opportunities for pharmaceutical firms considering alliances in China, based
on this research and the commitments made by Chinese authorities at the time
of accession to the WTO. The report concludes (section 5) by highlighting the
significant points for consideration for companies looking to capture such
business opportunities in China. The appendices (section 6) include two case
studies that explore examples of a 'Sino-foreign equity joint venture' and a
'Wholly foreign-owned company' in China, references, a glossary of terms, the
source data used in the figures, and a resources section.
Table of Contents
- 1. Introduction
- 2. An overview of the pharmaceutical industry in China
- 2.1. Economic reform and the open door policy in context
- 2.2. The growth of the Chinese pharmaceutical industry
- 2.3. The structure of the Chinese pharmaceutical industry
- 2.3.1. Industry output
- 2.3.2. Import and export
- 2.3.3. The industry layout
- 2.4. R&D in China
- 2.5. Marketing approvals and manufacturing
- 2.6. Non-Chinese investment enterprises in China
- 3. Competing in the international market
- 3.1. Introduction
- 3.2. Measuring trading competitiveness
- 3.3. Potential trading competitiveness
- 4. Business opportunities for non-Chinese pharmaceutical firms in China
- 4.1. Factors affecting business opportunities in China
- 4.1.1. Chinese Authorities' commitments and administrative measures
- 4.1.2. Chinese consumer demand for pharmaceutical products
- 4.2. The factors bringing business opportunities
- 4.3. How to capture business opportunities
- 4.4. Which would be the profitable fields for non-Chinese pharmaceutical
firms?
- 5. Conclusion
- 6. Appendices
- 6.1. Case studies
- 6.1.1. Sino-Swed Pharmaceutical Corp. LTD (SSPC)
- 6.1.2. Pfizer (China) Pharmaceuticals Limited
- 6.2. References
- 6.3. Glossary
- 6.4. Source data
- 6.5. Resources
- 6.6. Biography
List of Figures and Tables
- Figure 2.1 The output of the Chinese pharmaceutical industry
- Table 2.1 Value of the Chinese pharmaceutical industry in 2003
- Figure 2.2 Sub-sector revenue value as % of total
- Figure 2.3 Output value growth rate and net asset profit rate
- Figure 2.4 Pharmaceutical import and export
- Figure 2.5 Pharmaceutical enterprises in China
- Figure 2.6 Companies with in-house R&D
- Figure 2.7 Companies' commitment to R&D
- Figure 3.1 International trading competitive indices for pharmaceuticals
- Figure 3.2 Price indices of chemical raw materials for pharmaceuticals for
pharmaceuticals
- Table 3.1 Analysis of number of patent applications related to medicine
between 1990 and 2000
- Figure 3.3 Patent applications
- Figure 3.4 Percentage of patent applications granted for non-Chinese
applicants
- Figure 4.1 Chinese population and growth rate
- Figure 4.2 Chinese urban population and growth rate
- Figure 4.3 Chinese population demographics
